2012
Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis
Shefner J, Cedarbaum JM, Cudkowicz ME, Maragakis N, Lee J, Jones D, Watson ML, Mahoney K, Chen M, Saikali K, Mao J, Russell AJ, Hansen RL, Malik F, Wolff AA, Team F. Safety, tolerability and pharmacodynamics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis And Frontotemporal Degeneration 2012, 13: 430-438. PMID: 22591195, DOI: 10.3109/17482968.2012.684214.Peer-Reviewed Original ResearchConceptsAmyotrophic lateral sclerosisSingle dosesGlobal ImpressionLateral sclerosisFast skeletal muscle troponin activatorFrequent adverse eventsDose-related fashionLimb muscle strengthMaximum voluntary ventilationDose-dependent benefitMeasures of enduranceAdverse eventsPulmonary functionVoluntary ventilationGeneral fatigueTroponin activatorMuscle strengthPharmacodynamic markersHandgrip endurancePatientsRandom orderMaximal strengthDosesTolerabilityFurther studies
1995
Histometric effects of ciliary neurotrophic factor in wobbler mouse motor neuron disease
Ikeda K, Wong V, Holmlund T, Greene T, Cedarbaum J, Lindsay R, Mitsumoto H. Histometric effects of ciliary neurotrophic factor in wobbler mouse motor neuron disease. Annals Of Neurology 1995, 37: 47-54. PMID: 7818257, DOI: 10.1002/ana.410370110.Peer-Reviewed Original ResearchConceptsCiliary neurotrophic factorMotor neuron diseaseNeurotrophic factorMotor neuronsHuman ciliary neurotrophic factorNeuron diseaseWobbler miceWobbler mouse motor neuron diseaseMouse motor neuron diseaseCalcitonin gene-related peptideAcute axonal degenerationAxonal branching pointsBiceps muscle weightC5 ventral rootsGene-related peptidePercentage of axonsAtrophied muscle fibersUntreated control groupRat ciliary neurotrophic factorMean muscle fiber diameterMusculocutaneous nerveAxonal degenerationVentral rootsSubcutaneous injectionVacuolar degeneration